Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

HRMY vs AKRO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

HRMY Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 7–3 Matrix Metrics)

HRMY Overall Winner 6-Pillar Tally: HRMY 6 – 0 AKRO Matrix Metrics: HRMY 7 – 3 AKRO

As of Nov 20, 2026, Harmony Biosciences Holdings, Inc. (HRMY) is the stronger overall head-to-head candidate over Akero Therapeutics, Inc. (AKRO) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). HRMY carries a Unified Composite Score of 67.1/100 (BUY) at $32.59 (5.4x Forward P/E, 22.2% operating margin), whereas AKRO carries 60.0/100 (BUY) at $54.65 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: HRMY is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.4); meanwhile AKRO trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 67.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About HRMY vs AKRO
HRMY NASDAQ Head-to-Head Winner
Harmony Biosciences Holdings, Inc. Common Stock
Pharmaceutical Preparations
$32.59
-1.18% 1D
Market Cap $1.9B
TTM Revenue $989M
Forward P/E 5.4x
Beta / 30D Vol 0.55β · 38% Vol
Unified Composite Score
67.1 / 100 BUY
Tech 80.0 Fund 74.0 Flow 70.0 Mom 70.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -5.1%), weak momentum, RSI 32
RSI-14: 32.4 · SMA20: $34.97 · SMA50: $37.77
AKRO NASDAQ
Akero Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$54.65
+0.32% 1D
Market Cap $4.5B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.90β · 2% Vol
Unified Composite Score
60.0 / 100 BUY
Tech 55.0 Fund 52.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (7.8% over 20 days), RSI 67
RSI-14: 67.3 · SMA20: $54.36 · SMA50: $52.91

6-Pillar Scorecard Institutional Category Breakdown (HRMY 6 – 0 AKRO)

Columns: Metric · HRMY · AKRO
1. Valuation Multiples HRMY
Forward P/E 5.4x N/M
Trailing P/E 10.9x N/M
PEG Ratio N/M N/M
EV / Revenue 1.5x N/M
2. Growth & Scale HRMY
Revenue Growth (YoY) +12.3% +0.0%
Earnings Growth (YoY) -6.9% +0.0%
TTM Revenue (USD) $989M N/A
Market Cap $1.9B $4.5B
3. Profitability & Quality HRMY
Gross Margin 74.0% N/A
Operating Margin 22.2% 0.0%
Net Profit Margin 18.1% 0.0%
Return on Equity (ROE) 18.7% -34.5%
4. Balance Sheet & Cash Flow HRMY
Cash Generation (TTM) $323M N/A
Cash Flow Margin 32.6% N/A
Net Cash / Leverage $498M Net Cash $11.95 Book/Sh · -34.5% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning HRMY
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 72.4% (11th %ile) 7.3% (30th %ile)
Put/Call OI Skew 4.40x (Put-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat HRMY
OpEx & R&D Intensity 51.8% of Rev ($512M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Pharmaceutical Preparations Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: HRMY (7) vs AKRO (3)
Institutional Metric HRMY AKRO Criterion Row Edge
Market Capitalization
Scale
$1.9B $4.5B Larger Scale AKRO
Trailing P/E Ratio
Valuation
10.9x N/M Lower Multiple HRMY
Forward P/E Ratio
Valuation
5.4x N/M Lower Multiple HRMY
Revenue Growth (YoY)
Growth
+12.3% +0.0% Higher Growth HRMY
Operating Margin (TTM)
Profitability
22.2% 0.0% Higher Margin HRMY
Net Profit Margin
Profitability
18.1% 0.0% Higher Margin HRMY
Return on Equity (ROE)
Capital Efficiency
18.7% -34.5% Higher ROE HRMY
52-Week Range Position
Momentum
38% ($26–$43) 90% ($21–$58) Stronger Trend AKRO
Beta / 30D Volatility
Risk Regime
0.55β · 38% Vol 0.90β · 2% Vol Lower Realized Risk AKRO
Unified Institutional Score
Composite Signal
67.1 / 100 (BUY) 60.0 / 100 (BUY) Higher Composite HRMY
Trailing 12M Revenue (USD)
Operating Scale
$989M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
74.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.5x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$323M ($498M Net Cash) N/A ($11.95 Book/Sh · -34.5% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon HRMY +16.27 pp
HRMY: +16.84% · AKRO: +0.57%
3M Horizon HRMY +16.27 pp
HRMY: +16.84% · AKRO: +0.57%
6M Horizon HRMY +16.27 pp
HRMY: +16.84% · AKRO: +0.57%
1Y Horizon HRMY +16.27 pp
HRMY: +16.84% · AKRO: +0.57%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on HRMY vs AKRO. Trailing 12-month operating profitability (HRMY 22.2% vs AKRO 0.0%) and valuation multiples (HRMY 5.4x vs AKRO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

HRMY ADR TTM Benchmark FX-Normalized USD
TTM Revenue$989M
Gross Margin74.0%
Op. Margin22.2%
ROE / Fwd P/E18.7% · 5.4x
AKRO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-34.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
HRMY CONSOLIDATION
114d in phase · OBV DISTRIBUTION
Current IV 72.4%
IV Percentile 11th %ile
Put/Call OI Skew 4.40x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact HRMY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AKRO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 7.3%
IV Percentile 30th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AKRO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $33.20 · IV 76.7%

HRMY Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($3,320)

Compare $3,320 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 76.7% ATM IV.

PUT-WALL MONTHLY INCOME Liq B

Dec 18 $30 / $27.5 Bull Put Spread

Sell 2x $30P · Buy 2x $27.5P · 30d

Net Entry $60 Credit
Max Credit / Yield +$60 (+13.6% RoM)
Max Risk / Buffer -10.5% Cushion ($440 Mgn)
5d Edge & Liquidity 78% PoP · Liq B
Simulate 5-Day Payoff →
5-DAY DOWNSIDE SPREAD Liq B

Dec 18 $35 / $30 Bear Put Spread

Buy 1x $35P · Sell 1x $30P · 30d

Net Entry $230 Debit
T+5d @ -5% Drop +$67 (+29%)
Max Risk / Buffer $230 Capped
5d Edge & Liquidity 0.8x R:R · Liq B
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
HRMY Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $1.9B market capitalization and 22.2% operating margin.
OpEx & R&D Reinvestment 51.8% of Rev ($512M)
90D Engineering Disclosures 0 Published
AKRO Moat Profile Cyclical / Execution-Driven Positioning
Pharmaceutical Preparations Operator
Competes within the Pharmaceutical Preparations value chain with $4.5B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ HRMY vs AKRO Key Questions & Quantitative Answers

As of Nov 20, 2026, Harmony Biosciences Holdings, Inc. (HRMY) is the stronger overall head-to-head candidate over Akero Therapeutics, Inc. (AKRO) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). HRMY carries a Unified Composite Score of 67.1/100 (BUY) at $32.59 (5.4x Forward P/E, 22.2% operating margin), whereas AKRO carries 60.0/100 (BUY) at $54.65 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: HRMY is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.4); meanwhile AKRO trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 67.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

HRMY leads the Growth & Scale pillar: HRMY posts +12.3% YoY revenue growth and -6.9% YoY earnings growth on $989M TTM revenue (74.0% gross margin, 22.2% operating margin), compared with AKRO at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, HRMY generates $989M in USD-normalized revenue versus N/A for AKRO. In operating R&D and SG&A reinvestment, HRMY deploys 51.8% of Rev ($512M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AKRO.

HRMY screens cheaper on headline valuation multiples. HRMY trades at 5.4x Forward P/E, 10.9x Trailing P/E, N/M PEG, and 1.5x EV/Revenue (32.6% FCF margin), whereas AKRO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against HRMY (18.7% ROE) versus AKRO (-34.5% ROE) capital efficiency.

In options market volatility and institutional positioning, HRMY carries 72.4% implied volatility (11th %ile, Compressed (<25th %ile)), a 4.40x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.55β · 38% Vol realized risk). By comparison, AKRO carries 7.3% implied volatility (30th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.90β · 2% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.